Generics win major court case
Article Abstract:
The Supreme Court of Canada has overturned decisions keeping two generic drugs off the market. The verdict is major victory for Apotex Inc. and Novopharm Ltd., which manufacture the generic drugs. The ruling would also mean that Canadian consumers would be paying less for the drugs, which are an antibiotic and an ulcer treatment. Canadians have been paying more than C$12 million for the two drugs since 1993 due to the regulations and the litigation brought by Eli Lilly Canada Inc. and Merck Frosst Canada Inc. Meanwhile, an official with Industry Canada, said that the department is reviewing the judgment.
Comment:
Canada: The country's Supreme Court has overturned decisions keeping two generic drugs off the market
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Court stays prohibition of generic AZT sales
Article Abstract:
An earlier court ruling was nullified by the Federal Court Appeal, which allowed generic drug makers in Canada to continue selling their less expensive versions of the AIDS drug, AZT. The previous ruling prohibited manufacturers Apotex Inc., Toronto, Canada-based Novopharm Ltd. and Interpharm Inc. from making and selling their versions of AZT in Canada until the year 2005. Novopharm Chairman and CEO Leslie Dan, said the generic versions of the drug typically sell for at least 30% to 40% lower than the branded version by Glaxo Wellcome Inc.
Comment:
Canada: The Federal Court Appeal allowed generic drug makers in Canada to continue selling less expensive versions of AZT
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Generics lash out at health regulations
Article Abstract:
The Canadian generic drug industry has criticized the federal health regulations that slowed down the introduction of low-cost generic versions of expensive drugs. The 1993 legislation provided a 20-yr patent protection to manufacturers of name-brand drugs. The law counterbalanced regulations that give generic drug makers access to patented formulas and stockpile low-cost versions when the patent is running out
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: The enforcers: medical colleges are taking aim at some alternative practitioners. Wheezing and worrying
- Abstracts: One Nation, another country. Hanson heads for the exit. The man from Manly waves the baton
- Abstracts: Ontario court backs Sun Life deal. Court rules against Great-West. Sun Life ordered to pay penalty in fraud case
- Abstracts: SouthernEra, New Indigo in merger talks. The tangled tale of Lytton
- Abstracts: Philip finds saviour investors. Spar shareholders launch revolt